Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Our AI scores Revvity, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Revvity, Inc. is a large-cap company with a market capitalization of $17.31B. It ranks number 5 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
For RVTY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 61.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RVTY included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
| Metric | RVTY | Rank |
|---|---|---|
| Market Cap | $17.31B | 5/25 |
| P/E Ratio | 74.57x | 3/8 |
| P/B Ratio | 2.39x | 11/23 |
| Dividend Yield | 0.18% | – |
| EPS | $2.08 | – |
| Book Value/Share | $64.78 | – |
| Revenue/Share | $26.09 | – |
| FCF/Share | $5.00 | – |
| Metric | RVTY | Rank |
|---|---|---|
| ROE | 3.3% | 6/19 |
| ROA | 2.0% | 6/18 |
| ROIC | 3.3% | 4/20 |
| Gross Margin | 55.8% | 5/19 |
| Operating Margin | 12.3% | 3/21 |
| Net Margin | 8.2% | 5/17 |
| EBT Margin | 9.0% | 5/22 |
| Tax Rate | 9.0% | – |
| Metric | RVTY | Rank |
|---|---|---|
| Current Ratio | 1.80x | 23/25 |
| Quick Ratio | 1.50x | 19/24 |
| D/E Ratio | 0.67x | 9/24 |
| Financial Leverage | 1.67x | 9/23 |
| Interest Coverage | 1.3x | 5/21 |
| Working Capital | $1.02B | 6/25 |
| Metric | RVTY | Rank |
|---|---|---|
| Operating Cash Flow | $628M | 4/24 |
| Free Cash Flow | $558M | 4/20 |
| Capital Spending | -$70M | 14/20 |
| OCF Growth YoY | 7.4% | 6/11 |
| FCF Growth YoY | 11.0% | 4/9 |
| FCF/Sales | 19.2% | 3/19 |
| CapEx/Sales | 2.4% | 11/19 |
| Metric | RVTY | Rank |
|---|---|---|
| Asset Turnover | 0.24x | 16/20 |
| Receivables Turnover | 4.1x | 17/19 |
| Inventory Turnover | 3.4x | 4/19 |
| Fixed Assets Turnover | 6.4x | 7/21 |
| Days Sales Outstanding | 89 days | 3/19 |
| Days Inventory | 107 days | 16/19 |
| Payables Period | 47 days | 9/18 |
| Cash Conversion Cycle | 149 days | 11/17 |
| Metric | RVTY | Rank |
|---|---|---|
| Total Revenue | $2.91B | 7/21 |
| Operating Income | $359M | 4/21 |
| Net Income | $238M | 6/19 |
| R&D Expense | $216M | 8/21 |
| SG&A Expense | $1.03B | 6/20 |
| Cost of Goods Sold | $1.29B | 6/19 |
| Metric | RVTY | Rank |
|---|---|---|
| Dividends Per Share | $0.28 | – |
| Payout Ratio | 13.5% | – |
| Shares Outstanding | 112M | – |
| Net Income Growth | -16.7% | – |
| EPS Growth | -5.9% | 5/7 |
| Total Current Assets | $2.30B | 19.1% of assets |
| Cash & Short-term Investments | $1.02B | 8.5% of assets |
| Accounts Receivable | $709M | 5.9% of assets |
| Inventory | $378M | 3.1% of assets |
| Total Liabilities | $4.82B | 40.0% of assets |
| Short-term Debt | $1.11B | 9.2% of assets |
Companies classified under the same SEC industry code as Revvity, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| RVTY Revvity, Inc. | $17.31B | |
| A Agilent Technologies, Inc. | $49.27B | |
| WAT Waters Corp /De/ | $44.51B | |
| MTD Mettler Toledo International Inc/ | $33.64B | |
| ILMN Illumina, Inc. | $32.23B | |
| AVTR Avantor, Inc. | $10.48B | |
| BIO Bio-Rad Laboratories, Inc. | $10.20B | |
| BRKR Bruker Corp | $9.34B | |
| TXG 10x Genomics, Inc. | $7.72B | |
| ALMR Alamar Biosciences, Inc. | $1.95B | |
| CTKB Cytek Biosciences, Inc. | $758M | |
| PACB Pacific Biosciences Of California, Inc. | $755M | |
| MASS 908 Devices Inc. | $436M | |
| NAUT Nautilus Biotechnology, Inc. | $284M | |
| BFNH Bioforce Nanosciences Holdings, Inc. | $210M | |
| QTRX Quanterix Corp | $131M | |
| SEER Seer, Inc. | $90M | |
| HBIO Harvard Bioscience Inc | $39M | |
| RPID Rapid Micro Biosystems, Inc. | $35M | |
| PRPO Precipio, Inc. | $33M | |
| EYPT Eyepoint, Inc. | $31M | |
| BNGO Bionano Genomics, Inc. | $13M | |
| LCTC Lifeloc Technologies, Inc | $9M | |
| ASTC Astrotech Corp | $8M | |
| SCND Scientific Industries Inc | $7M |
Revvity, Inc. (NYSE:RVTY) shares rose 5.55% in US premarket trading on Tuesday after the health sciences technology company reported stronger-than-expected third-quarter 2026 earnings and revenue and ...
<?xml encoding="utf-8" ?> Revvity Inc. RVTY stock hit a new 52-week high Tuesday after the life sciences company reported ...
Shares of Revvity ( RVTY ), a health-science technology company, rose nearly 8% on Tuesday after the company reported ...
Our AI scores Revvity, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For RVTY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 61.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Revvity, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
25 issuers in our coverage, RVTY included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Mettler Toledo International Inc/ (MTD), Illumina, Inc. (ILMN), Avantor, Inc. (AVTR), Bio-Rad Laboratories, Inc. (BIO).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
